产品
编 号：F741504
分子式：C16H19F3N4O2S
分子量：388.41
分子式：C16H19F3N4O2S
分子量：388.41
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2322245-42-9
产品详情
生物活性：
SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes.
体内研究：
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) decreases glucagon secretion and action and blocks hepatic glucose output.SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice.SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice.Animal Model:C57BL/6J mice
Dosage:100 mg/kg
Administration:Oral administration (p.o.), in drinking water, 3 weeks.
Result:Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice.
体外研究：
SRI-37330 (1 μM, 24 h) inhibits the activity of the human TXNIP promoter in INS-1 cells.SRI-37330 (1 μM, 24 h) inhibits Mrna and protein levels of TXNIP in INS-1 cells.SRI-37330 (5 μM, 24 h) inhibits polymerase II (Pol II) binding to the E-box motif region of the TXNIP promoter.SRI-37330 (5 μM, 24 h) lowers glucagon secretion in TC1-6 cells.SRI-37330 (0-5 μM, 24 h) inhibits glucagon-induced glucose output from primary hepatocytes.
SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes.
体内研究：
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) decreases glucagon secretion and action and blocks hepatic glucose output.SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice.SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice.Animal Model:C57BL/6J mice
Dosage:100 mg/kg
Administration:Oral administration (p.o.), in drinking water, 3 weeks.
Result:Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice.
体外研究：
SRI-37330 (1 μM, 24 h) inhibits the activity of the human TXNIP promoter in INS-1 cells.SRI-37330 (1 μM, 24 h) inhibits Mrna and protein levels of TXNIP in INS-1 cells.SRI-37330 (5 μM, 24 h) inhibits polymerase II (Pol II) binding to the E-box motif region of the TXNIP promoter.SRI-37330 (5 μM, 24 h) lowers glucagon secretion in TC1-6 cells.SRI-37330 (0-5 μM, 24 h) inhibits glucagon-induced glucose output from primary hepatocytes.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备